Enhancement of host defence by Y-19995 (2,4'-bis(1-methyl-2-dimethyl-aminoethoxyl)-3-benzoylpyridine dimaleate), a novel synthetic compound. I. Accelerated restoration from the leukocytopenia and augmented protection against microbial infections in immunocompromised mice.
Effects of a novel synthetic compound, Y-19995, on the host defence in immunocompromised mice were investigated in terms of the restoration of leukocytopenia and the protection against several microbial infections. Oral or intravenous administration of Y-19995 into mice after X-irradiation, treatment with cyclophosphamide or mitomycin C prevented the leukocytopenia to some extent and promoted the restoration in cell numbers of both the peripheral blood leukocytes and bone marrow. Intravenous administration of Y-19995 increased significantly the survival rates of X-ray irradiated mice against acute systemic infections with Escherichia coli, Pseudomonas aeruginosa and Candida albicans, and intramuscular infection with Escherichia coli. The clearance of Escherichia coli from the blood of X-ray irradiated mice was also promoted by the treatment with Y-19995. The augmented protection against microbial infections in immunocompromised hosts by Y-19995 may be attributed mainly to the prevention of leukocytopenia or the enhanced restoration from leukocytopenia.
Fujisawa
H
H
Department of Microbiology, National Defence Medical College, Saitama, Japan.
Tsuru
S
S
Hisatome
M
M
Goto
K
K
Oe
T
T
Okumoto
T
T
Taniguchi
M
M
Nomoto
K
K
D000818:Animals; D001424:Bacterial Infections / Q000188:drug therapy / Q000276:immunology*; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D002177:Candidiasis / Q000188:drug therapy / Q000276:immunology; D003520:Cyclophosphamide; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000276:immunology; D007165:Immunosuppression Therapy; D007958:Leukocyte Count / Q000187:drug effects*; D007970:Leukopenia / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR / Q000528:radiation effects; D008937:Mitomycins; D010844:Picibanil / Q000494:pharmacology; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000276:immunology; D011725:Pyridines / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology*
D008937:Mitomycins; D011725:Pyridines; C054098:Y 19995; D010844:Picibanil; D003520:Cyclophosphamide